ASSET - AI for Sustainable Prevention of Autoimmunity in the Society
|Coordinator||Diamyd Medical AB|
|Funding from Vinnova||SEK 39 902 296|
|Project duration||September 2021 - September 2026|
|Venture||Innovation milieus in precision health|
|Call||Innovation milieus in precision Health 2021|
Purpose and goal
The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) aims to develop and evaluate new algorithms based on artificial intelligence (AI) for preventive precision medical treatments for type 1 diabetes and other autoimmune diseases. In parallel, ASSET will study the organizational and legal conditions for healthcare to apply the proposed precision health solutions in the Swedish healthcare system.
Expected results and effects
The project will answer both technical and organizational questions about whether and how it is possible to carry out screening of type 1 diabetes and other autoimmune diseases at national level as well as to preventatively treat individuals at a high risk of being diagnosed.
Planned approach and implementation
The project is divided into three main phases. 1) ASSET Development where the technical basis for the AI algorithm is laid and preparations for a pilot study are carried out, 2) ASSET Pilot where a prospective screening and prevention study is carried out based on the AI algorithm, and 3) ASSET Scale-up where lessons from the previous phases are implemented on a larger scale.